SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: Dr. John M. de Castro who wrote (896)9/8/1999 6:44:00 PM
From: arnie h  Read Replies (1) | Respond to of 1386
 
Dr. John: As I recall, placebo had lower than usual mortality in cohorts 1 and 2 so your cautionary stance seems quite warranted.
I had thought Cohort 3 would be available sometime this year.
Is this no longer so?
Arnie



To: Dr. John M. de Castro who wrote (896)9/8/1999 9:18:00 PM
From: yosi s  Respond to of 1386
 
What I try to point out is that cohort 3 total mortality is lower than 2.
So I expect HU 211 to cohort 3 to confirm the data.
It is important as 2/3 of cohort 3 is active arm.
It almost doubles the active arm. or treated group.

And with small numbers published to date it is very nice to see further trends toward efficacy of HU 211


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News